Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a large decline in short interest in January. As of January 15th, there was short interest totalling 55,700 shares, a decline of 98.8% from the December 31st total of 4,710,000 shares. Based on an average daily trading volume, of 7,300,000 shares, the days-to-cover ratio is presently 0.0 days.

Vincerx Pharma Trading Up 5.3 %

Shares of VINC traded up $0.08 during mid-day trading on Friday, reaching $1.58. 376,219 shares of the stock traded hands, compared to its average volume of 1,112,746. The company has a market cap of $2.65 million, a price-to-earnings ratio of -0.08 and a beta of 1.48. Vincerx Pharma has a 1 year low of $1.40 and a 1 year high of $187.44. The firm has a fifty day moving average price of $3.87 and a 200 day moving average price of $8.71.

Institutional Trading of Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 328,533 shares of the company’s stock after buying an additional 256,967 shares during the period. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 44.02% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Leerink Partners lowered their price target on shares of Vincerx Pharma from $80.00 to $40.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.